PMLS Virtual Series – RTP/Population Health

Unable to attend? On Demand Here

October 20-21, 2020

9:00 – 9:10

Welcome & Introduction

Geoff Ginsburg, MD, PhD,  Director of Duke Center for Applied Genomics and Precision Medicine, Professor of Medicine,  Sara Imhof, PhD Senior Director, Precision Health, Nigel Russell, President and Founder, Precision Medicine Leaders’ Summits and The Journal of Precision Medicine

9:10 – 9:50

Keynote: From Precision Medicine to Precision Public Health: Opportunities and Challenges

Advances in genomics and precision health technologies are changing the practice of medicine and public health. In this talk, I will explore the historical evolution and impact of genomics and related technologies on population health. I will explore the public health response to genomics and precision health technologies, using specific examples from CDC and public health programs to illustrate the current opportunities and challenges of new technologies in improving population health and preventing disease.

Muin Khoury, MD, PhD, Director, Office of Genomics and Precision Public Health, CDC

9:50 – 10:10

The State of the Evidence for Using Genetics in Population Screening

• CDC Tier 1 vs ACMG59
• The importance of considering disease prevalence on PPV
• Methods for avoiding false positives in setting of low disease prevalence

Jill Hagenkord, MD, FCAP, Chief Medical Officer, Optum Genomics

10:10 – 10:20

Break

10:20 – 10:50

Keynote: The Role of the Environment in Precision Medicine

Rick Woychik, PhD, Director, National Institute of Environmental Health Sciences, National Institutes of Health

The Human Genome Project has provided the transformative genome analysis tools that are helping to usher in a new era of Precision Medicine.  The recently launched International Common Disease Alliance (ICDA) is working to define a new set of objectives that aim to bring greater cooperation across the global biomedical community and to enable a new research platform called Maps to Mechanisms to Medicine program (M2M2M). The objectives of this new program are to better understand that complex traits associated with common disease, decipher disease mechanisms, and build strong programs that will systematically bring complex traits and disease mechanisms into the clinic and public health communities. Through the Personalized Environment and Genetics Study (PEGS), NIEHS is collecting data on exposures in participants from NC that will be combined with genetic analysis and information from electronic health records on common disease phenotypes. Integrating environmental exposures data and environmentally-mediated epigenomic changes will ultimately provide a more complete data platform that can be applied to enable the emerging new programs in Precision Medicine.

10:50- 11:10

Delivering Precision Medicine to the Patients in Community-Based Populations

Edward S. Kim, MD, FACP, Chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Atrium Health

11:10 – 12:00 Noon

Using Data to Enable Precision Health Programs

Moderator: Rebecca Boyles, MS, Senior Scientist, Bioinformatics and Data Science at RTI International

Panelists: Melissa Haendel, PhD, Director, Translational and Integrative Sciences Center, Oregon State University, Kelci Miclaus,PhD, Senior Manager, Advanced Analytics R&D, JMP Life Sciences. Jessie Tenenbaum, PhD, Chief Data Officer, NC Department of Health and Human Services

DAY 2

9:00 – 9:05

Welcome & Day One Recap

Geoff Ginsburg, MD, PhD,  Director of Duke Center for Applied Genomics and Precision Medicine, Professor of Medicine,  Sara Imhof, PhD Senior Director, Precision Health, Nigel Russell, President and Founder, Precision Medicine Leaders’ Summits and The Journal of Precision Medicine

9:05 – 9:35

Keynote – Precision Health Policy

Mark McClellan, MD, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Duke-Margolis Center for Health Policy at Duke University

9:35 – 10:00

Policy Challenges and Opportunities with Precision Health Innovation

Marianne Hamilton Lopez, PhD, MPA, Research Director, Duke-Robert J. Margolis, MD, Center for Health Policy

10:00 – 10:20

COVIDentify

Jessilyn Dunn, PhD Assistant Professor of Biomedical Engineering and Biostatistics & Bioinformatics, Duke University

10:20 – 10:30

Break

10:30 – 10:50

Population Health, the NHS and COVID-19

Professor Dame Sue Hill DBE FMedSci FRSB FRCP (Hon) FRCPath(Hon), Chief Scientific Officer and SRO for Genomics, NHS England

10:50 – 11:10

Precision 20 – Critical Success Factors for Addressing the Next Generation of Precision Medicine

Eric Faulkner, MPH, Vice President, Precision and Transformative Medicine, Evidera

11:10 – 11:55

The Young Investigators

One-year cost-effectiveness of CYP2C19-guided de-escalation and escalation of P2Y12 inhibitors in Veterans with acute coronary syndromes undergoing percutaneous coronary intervention –

Olivia Dong, PhD, MPH, Duke University

Clinically relevant phenotypes of type 1 diabetes (T1D): proof of principle for precision health in chronic disease and next steps for translation

Anna Kahkoska PhD UNC

Immuno-Reactive Cancer Organoid Models to Examine Microbiome Metabolite Effects on Immune Checkpoint Blockade Efficacy

Ethan Shelkey Graduate Student, Wake Forest

Personalized Risk Predictions of the Microvascular Complications of Diabetes using the SMART Framework

Breanna Swan, MS, Graduate Student, NCSU

11:55 – 12 noon

Closing Remarks

Geoff Ginsburg, MD, PhD,  Director of Duke Center for Applied Genomics and Precision Medicine, Professor of Medicine,  Sara Imhof, PhD Senior Director, Precision Health, Nigel Russell, President and Founder, Precision Medicine Leaders’ Summits and The Journal of Precision Medicine